EPISODE · Oct 5, 2022 · 11 MIN
Kesimpta More Cost-Effective for RRMS & Following My Own (MS) Advice.
from MS News & Perspectives · host MS News Today
Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, reads a new analysis regarding the fact that in Canada, Kesimpta is more cost-effective than other DMTs for treating relapsing-remitting MS.He also reads “My Wife Says I Should Follow My Own (MS) Advice” by Ed Tobias, from his column “The MS Wire”. =================================== Are you interested in learning more about multiple sclerosis? If so, please visit:https://multiplesclerosisnewstoday.com/=====================================To join in on conversations regarding multiple sclerosis, please visit:https://multiplesclerosisnewstoday.com/forums/
Embed this episode
NOW PLAYING
Kesimpta More Cost-Effective for RRMS & Following My Own (MS) Advice.
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.